Medigene secures SynCore as global partner for EndoTAG-1
German biotech firm Medigene (MDG: GR) has secured SynCore Biotechnology (part of Taiwan’s Sinphar Pharmaceutical Group) as a strategic (6%) investor and now global partner for EndoTAG-1, an extension of its July 2012 deal for Asian rights to the compound. A global Phase III study of EndoTAG-1 in triple negative breast cancer is expected to start in first-half 2014.
The deal removes prior uncertainty over EndoTAG’s future, say analysts at Edison Investment Research, who have raised their probability of success for EndoTAG-1 from 35% to 50%. Adding the 2.4 million euros ($3.0 million) upfront from SynCore’s purchase of 2.4 million new MediGene shares, their overall valuation increases to 85 million euros, or 2.15 euros per share.
EndoTAG-1 can now advance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze